Recordati Rare Diseases Canada, a unit of Recordati (REC.MI) on Tuesday announced that Isturisa, for the treatment of Cushing's disease, is now available in Canada. The launch follows the drug's marketing authorization in Canada on July 5, 2025.
Cushing's disease is a specific form of Cushing's syndrome, caused by prolonged exposure to excessive levels of the hormone cortisol.
Isturisa's approval was supported by data from the LINC 3 and LINC 4 Phase III studies, which showed clinically meaningful reductions in mean urinary free cortisol (mUFC) levels and demonstrated a favorable safety profile.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.